Pfizer Shares Face a Multifaceted Squeeze

The pharmaceutical giant Pfizer is navigating a challenging start to 2026, caught in a crossfire of financial, regulatory, and competitive pressures. As the company contends with disappointing guidance and new pricing frameworks, investors are questioning whether its early strategic adjustments will pay off and if its substantial dividend can offset ongoing share price weakness.

Pfizer’s recent financial forecast has dampened market sentiment. For the full year 2026, management provided an adjusted earnings per share (EPS) guidance range of $2.80 to $3.00, falling short of analyst expectations which had exceeded $3.05. This cautious outlook is primarily driven by two significant revenue drains:
* A continued decline in COVID-related product sales, expected to reduce revenue by approximately Read more...